top of page
Song Kim, COO (1).png

Removing barriers to quality care through
point of care blood monitoring 

Our Vision 

We care deeply about addressing systemic injustices that deprive people of basic rights. We believe that regardless of income, race, gender, sexuality, or any other circumstances of birth, no one should have to forgo healthcare due to a lack of resources.

Starting with Sickle Cell Disease (SCD), we will apply our proprietary 3D phase imaging microscope and deep learning algorithms to empower patients and their providers to take a proactive, rather than reactive, approach to managing their health.


Sickle Cell Disease

(by the numbers)

people affected around the world

30 M

preventable deaths every year


shorter life expectancy


of hospitalization each year

13+ DAYS

in lifetime treatment costs

$1M - $9M

Home: Our Technology

Our Solution

KovaDx is building a tool that will allow for ongoing monitoring and preventative care for individuals with rare blood diseases.


Our device utilizes 3D Quantitative Phase Imaging (QPI) to obtain data about human red blood cells to create a Red Blood Cell Health Index.


AI Image Edit2.png

Bridging the Divide

Decrease in childhood mortality in low-income countries by Increasing access to affordable and accurate lifesaving diagnostics at birth.


Significantly improve quality of life for patients living with sickle cell disease in the U.S. and other high-income countries by preventing debilitating sickling crises.


Accelerate much-needed research for sickle cell disease by building first of its kind database of 3D-phase images of sickle cells.


Why Now

Change in Tide of Historic Underinvestment

Investment into health equity and access in recent years, in response to a national reckoning around racial injustice, has impacted funding and investment into Sickle Cell Disease.

Covid Pandemic and Remote Care

The Covid pandemic has demonstrated the need for and promise for decentralized models of care and access.

Advances in Technology

Exponential advances in AI have made it possible to process the amount of data our system is capable of in a short amount of time.

Evolving Pharmacotherapeutic Landscape

There are only few FDA-approved drugs to treat SCD, illustrating the high unmet need for new therapies. The presence of strong key market players with strong pipelines predicts market growth.


In Development

Sickle Cell Disease

Rare Blood Diseases



Blood Cancers

Multiple Myeloma 


We'd love to connect!

  • LinkedIn

Thanks for being in touch!

bottom of page